SA author defends Oramed, shares rise


Seeking Alpha author Sharon de Stefano jumps to Oramed's (ORMP +6.7%) defense after the tongue lashing the company received from Adam Feuerstein over Phase IIa trial results sent its shares into a tailspin.

Feuerstein focused on a chart which showed what appeared to be high rates of adverse events.

However, de Stefano accuses Feuerstein of not distinguishing between the levels of those events, and implies that he doesn't know what he's talking about. "Clinical data is often difficult for physicians to interpret, much less laymen, and jumping to inaccurate conclusions is not uncommon," de Stefano writes.

The side effects in the Oramed study were dizziness, nausea, constipation and headaches, which are "of little concern to the FDA in a diabetes study," says de Stefano.

From other sites
Comments (5)
  • Non-Plused
    , contributor
    Comments (101) | Send Message
     
    As a Type II diabetic I have refused to take medications with the side effects he says are of no concern. There are medications without that cocktail of side effects. No need to subject yourself to them. Stefano's logic is specious.
    5 Feb 2014, 09:05 AM Reply Like
  • l.f.hans@hotmail.com
    , contributor
    Comments (2) | Send Message
     
    In such a small cohort, statistically, no conclusions could possibly be drawn. The FDA ordered this study to rule out the possibility the non-FDA studies were flawed in the safety protocols.
    Therefore, Sharon is correct and the other guy is either a novice or needs a crash course in biostatistics.
    lfh of FL
    5 Feb 2014, 08:08 PM Reply Like
  • JRSalazar
    , contributor
    Comments (2) | Send Message
     
    As an RN for over 2 decades, I've seen my fair share of side effects (SE) of meds that the patients are subjected to because of the need to control their diabetes (DM). Some are not affected as much as others; but the lesser of the two evils is to take the med, deal with the SE or deal with the loss of limbs from not controlling the DM. Unfortunatly my own grandmother didn't think the same way and before dying from complications of DM, she had both of her limbs amputated below the knee. As for me, I was accidentally stuck with a needle that was just used on an HIV patient and had to be on 6 months of antiviral meds to make sure that I didn't convert to HIV my self. Let me tell you the SE are much worse; i.e. nausea, vomiting, diarrhea, extreme fatigue and constant headaches. But either take a chance of converting or not, I chose to take 3 separate medications at the same time while still going to work to support my family. The N/V/D SE were worth not coverting to save my own health/life just as the SE of ORMP's med to help control DM orally will definitely be worth it.
    5 Feb 2014, 08:12 PM Reply Like
  • wimkesini
    , contributor
    Comments (23) | Send Message
     
    where''s the official comment?
    $16: a buying opportunity or a dead cat?
    5 Feb 2014, 08:32 PM Reply Like
  • sparkinson
    , contributor
    Comments (64) | Send Message
     
    there are always naysayers when their competitors succeed where theyvare failing to do so! look out for those who knock the competitors without a reason!!! you go Oramed!!
    6 Feb 2014, 05:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs